News & Events Archives - Page 2 of 21

Category: News & Events

Catheter Ablation as the First-Line Therapy for Atrial Fibrillation: Update on Evidence and Clinical Implications

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Therapy for atrial fibrillation has markedly evolved over the past two decades. Advancements in technology and growing therapeutic options have led to reexamination of the current evidence. New guidelines have also been updated and published across continents. This reappraisal of the contemporary data assesses the overall treatment strategies for patients with atrial fibrillation and examines how atrial fibrillation ablation ranks among the hierarchy of therapeutic modalities. The role of catheter ablation as a first-line therapy in selected patients with atrial fibrillation is emphasized, and a selective discussion of catheter ablation in patients with heart failure is included.

(more…)

Opioid-sparing Anesthesia Significantly Improves Early Postoperative Recovery after Cardiac Surgery: A Retrospective Cohort Study

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Mounting evidence indicates that opioid-sparing anesthesia (OSA) decreases opioid-related adverse events. This article examines whether OSA might improve initial recovery after cardiac surgery.

Data from patients who underwent elective heart surgery between July 2023 and July 2024 were analyzed. Eligible patients were divided into an OSA group or a control group. Patients in the OSA group received 0.5 to 1 μg·kg⁻¹ sufentanil and ultrasound-guided nerve block after anesthetic induction, whereas patients in the control group received traditional high-dose opioid management. Patients in both groups were managed with the same sedatives, muscle relaxants, and other drugs. The main outcome was the overall 15-item Quality of Recovery (QoR-15) survey score 24 hours after surgery. (more…)

Interventional Therapy in Pulmonary Embolism Treatment: Expanding Benefits and Advancing Safety

Acute pulmonary embolism (PE) remains a global health challenge with significant morbidity and mortality. High-risk PE, characterized by hemodynamic instability, and intermediate-risk PE, with evidence of right ventricular (RV) dysfunction, pose distinct therapeutic challenges. Traditionally, systemic thrombolysis and surgical embolectomy have been the primary therapeutic strategies. However, both approaches come with limitations, such as bleeding risks in thrombolysis and resource-intensive requirements in surgical embolectomy. In response, percutaneous catheter-directed therapies, including mechanical thrombectomy and catheter-directed thrombolysis (CDT), have emerged as promising alternatives.

(more…)

Comprehensive Strategies to Address Radiation-Induced Restrictive Cardiomyopathy

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Radiation-induced cardiomyopathy has become a significant clinical challenge with the increased use of thoracic radiation therapy. Recent technological advancements in radiation therapy, such as 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and proton therapy, have decreased cardiac exposure. Additional methods including multileaf collimation (MLC) cardiac shields, patient prone positioning, and the deep inspiration breath-hold (DIBH) technique further mitigate the effects of radiation on the heart. Post-therapy cardiac screening is crucial for timely intervention. Furthermore, the antioxidant properties of certain medications and herbal supplements may counteract radiation-induced oxidative stress. Notably, statins, angiotensin converting enzyme inhibitors, and natural products have demonstrated protective effects against radiation-induced cellular damage. (more…)

Cardiac Rehabilitation in Patients with Advanced Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Cardiac rehabilitation (CR) remains an integral part of heart failure (HF) management, yet certain groups of patients with HF, particularly those with implantable devices, and those who are older and/or frail, are often precluded from CR. The authors of this article performed a narrative review discussing the benefits of CR in these groups of patients, highlighting evidence from the existing literature. Special considerations for this patient group are further discussed, including CR implementation for their long-term management. Hesitancy in referring vulnerable groups of patients with HF, specifically those with advanced HF, has led to poor outcomes in this patient cohort. However, the growing evidence supporting the use of CR is discussed, thus demonstrating the importance of HF (more…)

Mechanical Thrombectomy System for the Treatment of Intermediate-Risk Acute Pulmonary Embolism: The CLEAR Study

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Mechanical thrombectomy is effective and safe for treating pulmonary embolism (PE). Although the Tendvia mechanical thrombectomy system has been validated in pigs, further evidence supporting its use in PE treatment is needed. This study was aimed at evaluating the safety and efficacy of the Tendvia system for intermediate-risk acute PE.

This prospective, single-arm, multicenter study included symptomatic patients with acute PE ≥18 years of age, with a right ventricular (RV)/left ventricular (LV) diameter ratio ≥0.9. The primary efficacy endpoint was the change in RV/LV diameter ratio from baseline to 48 hours postprocedure. The primary safety endpoint was the incidence of major adverse events (AEs), device-related death, 48-hour postprocedure major bleeding, pulmonary vascular injury, and cardiac injury.

(more…)

Comprehensive Bioinformatics Method to Explore Immune-Related Genes in the Pathogenesis of Myocardial Infarction

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at exploring immune-related genes and their expression changes in myocardial infarction (MI) through comprehensive bioinformatics methods and validating these genes as potential diagnostic and therapeutic targets.

Gene expression data were analyzed from three datasets: GSE29111 and GSE66360, which were combined as a training set, and GSE48060, which served as the validation set.

(more…)

Alternative RNA Splicing in Cardiac Diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Alternative splicing (AS), a critical process for gene expression regulation, allows a single precursor RNA to produce multiple transcript variants. Alterations in exon exclusion, intron retention, or the selection of alternative splice sites modify transcript isoforms, which can consequently affect RNA molecules, including mRNA and non-coding RNAs, in terms of their localization, regulation, and overall function.

In the cardiovascular system, AS of transcripts of sarcomere, ion channel, and cell signaling protein genes, as well as long non-coding RNAs, can contribute to the development of cardiovascular diseases. In addition, multiple hereditary heart-related diseases are caused by mutations associated with AS.

(more…)

Enhancing the Diagnosis of Transient Ischemic Attacks Through Biomarker Innovation

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study shows the potential of novel biomarkers in the diagnosis of TIA. Further research is warranted in testing more biomarkers including those omics markers for this purpose. Ultimately, to accurately identify TIAs from suspected cases will provide adequate and timely treatment and better patient care for those suffering with TIA.

(more…)

Mitochondrial Dysfunction as a Therapeutic Target in Diabetic Cardiomyopathy: Progress and Prospects

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and coronary artery disease, and is closely associated with the high incidence and mortality of heart failure in people with diabetes.

DCM causes microvascular disease, myocardial metabolic disorder, and myocardial fibrosis, thereby leading to left ventricular remodeling, diastolic and/or systolic dysfunction, and eventually progressing to congestive heart failure.

(more…)

← Older Posts

Newer Posts →